Trials / Completed
CompletedNCT01155999
Clinical Efficacy and Safety of T1225 Versus Tobramycin 0.3 % Eye Drops in the Treatment of Purulent Bacterial Conjunctivitis of Children.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 286 (actual)
- Sponsor
- Laboratoires Thea · Industry
- Sex
- All
- Age
- 1 Day – 18 Years
- Healthy volunteers
- Not accepted
Summary
Efficacy/Safety of T1225, in comparison to reference product, for the treatment of purulent bacterial conjunctivitis of children.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | T1225 | one drop twice daily (morning and evening) in each eye from Day 0 to Day 2 |
| DRUG | Tobramycin | 1 to 2 drops every two hours while awake on Days 0-1, up to 8×/day, then 1 to 2 drops 4 times daily on Days 2-6 |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2011-02-01
- Completion
- 2011-02-01
- First posted
- 2010-07-02
- Last updated
- 2014-10-29
- Results posted
- 2014-10-29
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01155999. Inclusion in this directory is not an endorsement.